Reneo Pharmaceuticals Files 8-K on Shareholder Vote Matters
Ticker: OKUR · Form: 8-K · Filed: Oct 2, 2024 · CIK: 1637715
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: RPHM
TL;DR
Reneo Pharma filed an 8-K on shareholder votes from Sept 26.
AI Summary
Reneo Pharmaceuticals, Inc. filed an 8-K on October 2, 2024, reporting on matters submitted to a vote of its security holders as of September 26, 2024. The filing details the company's corporate information, including its state of incorporation (Delaware), IRS number, and principal executive office address in Irvine, California.
Why It Matters
This filing provides an update on corporate governance activities, specifically concerning votes by Reneo Pharmaceuticals' shareholders.
Risk Assessment
Risk Level: low — This is a routine corporate filing detailing a shareholder vote, not indicating significant operational or financial changes.
Key Players & Entities
- Reneo Pharmaceuticals, Inc. (company) — Registrant
- September 26, 2024 (date) — Date of earliest event reported
- October 2, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- Irvine, California (location) — Address of principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on matters submitted to a vote of Reneo Pharmaceuticals, Inc.'s security holders.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is September 26, 2024.
In which state was Reneo Pharmaceuticals, Inc. incorporated?
Reneo Pharmaceuticals, Inc. was incorporated in Delaware.
What is the principal executive office address for Reneo Pharmaceuticals, Inc.?
The principal executive office address is 18575 Jamboree Road, Suite 275-S, Irvine, California, 92612.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (858) 283-0280.
Filing Stats: 1,718 words · 7 min read · ~6 pages · Grade level 12.2 · Accepted 2024-10-02 17:20:31
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share RPHM The Nasdaq Stock Mar
Filing Documents
- d870918d8k.htm (8-K) — 44KB
- 0001193125-24-231281.txt ( ) — 170KB
- rphm-20240926.xsd (EX-101.SCH) — 3KB
- rphm-20240926_lab.xml (EX-101.LAB) — 18KB
- rphm-20240926_pre.xml (EX-101.PRE) — 11KB
- d870918d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the proposed Merger and other statements that are not historical fact. All statements other than statements of historical fact contained in this Current Report on Form 8-K are forward-looking statements. These forward-looking statements are made as of the date they were first issued, and were based on the then-current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management. There can be no assurance that future developments affecting Reneo, OnKure or the proposed transaction will be those that have been anticipated. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Reneo's control. Reneo's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to the risk that the conditions to the closing of the proposed Merger are not satisfied. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled "Risk Factors" in Reneo's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC and subsequent Quarterly Reports on Form 10-Q, as well as the final proxy statement/prospectus on Form 424(b)(3) filed with the SEC on August 26, 2024. You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or a
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 2, 2024 Reneo Pharmaceuticals, Inc. By: /s/ Gregory J. Flesher Name: Gregory J. Flesher Title: President and Chief Executive Officer (Principal Executive Officer)